Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Analysts nudged up their target price for AMD to $636, from $629 previously. The chip giant carries a $1 trillion market cap and short interest of just 2.5% of free float. Broad buy-side support remains intact, with 43 analysts currently covering the stock.
Pfizer attracted fresh attention from Scotiabank. Analyst Louise Chen raised her target to $33 while reiterating a Buy rating. The stock's consensus target sits at $33, and short interest is low at 2.6% of free float. Medicare Advantage penetration hit 51.1% in June 2026, its highest ever reading since 2013, a structural tailwind that could support pharma demand across the sector.
William Blair initiated coverage of Revvity with a Buy rating. The life sciences tools firm has a market cap of $17.6 billion. Short interest stands at 6.2% of free float, above average for the space. The initiation adds a second buy-side voice to a stock where the consensus is already tilted positive.
On the materials side, consensus targets fell for both Vulcan Materials and Martin Marietta Materials. Vulcan's average target dropped to $315 from $317. Martin Marietta slipped to $641 from $646. Both stocks remain well-covered, but the direction of travel on price targets points to softer near-term expectations for construction demand.
Targa Resources and ConocoPhillips each saw their consensus targets edge higher, with buy-side sentiment in energy holding firm.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
